-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Spyre Therapeutics, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from 2020 to 2023.
- Spyre Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending September 30, 2024 was 1.06 USD/shares, a 23.3% increase year-over-year.
- Spyre Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending September 30, 2024 was -20 USD/shares, a 219% decline year-over-year.
- Spyre Therapeutics, Inc. annual Earnings Per Share, Diluted for 2023 was 13.8 USD/shares.
- Spyre Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was -24.9 USD/shares, a 0.64% increase from 2021.
- Spyre Therapeutics, Inc. annual Earnings Per Share, Diluted for 2021 was -25 USD/shares, a 1546% decline from 2020.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Growth (%)